Full-Time
Posted on 11/1/2025
Global pharmaceutical company delivering science-based innovations
$236.6k - $439.4k/yr
Livingston, NJ, USA
In Person
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Novartis closes factory in Wehr: 220 jobs cut. Pharma giant in Wehr Novartis closes factory near Swiss border - 220 jobs affected. The Swiss pharma giant is closing its production site in the southern German town of Wehr. It is no longer competitive. Published: 05.05.2026, 12:05 Swiss pharmaceutical giant Novartis plans to close its production site in Wehr, Baden-Württemberg, by the end of 2028. The Basel-based company announced that around 220 jobs would be cut. The reason for the decision: the site in the Waldshut district is no longer competitive. "We are aware of the uncertainty this announcement brings for our colleagues at the Wehr site," said production chief Steffen Lang. The company wants to work transparently and respectfully with employees and the municipality of Wehr. The Wehr site currently produces tablets and capsules. Novartis stressed that patient supply would not be endangered by the closure. The company reaffirmed its commitment to Germany as a location. At the same time, Novartis is investing 35 million euros in a new production facility for cancer therapies in Halle, Saxony-Anhalt, which is scheduled to start operations in 2027. According to its own information, Novartis employs over 2,600 people at six sites in Germany. Economy today Get the most important news from the economy, along with the best background information and analyses. More newsletters
NEW: Trump celebrates tariff triumph at steel rally, sparks manufacturing boom. At a lively gathering at the Coosa Steel plant in Rome, Georgia, former President Donald Trump proclaimed the triumph of his administration's tariffs as a catalyst for revitalizing American manufacturing. This rally, held on February 19, was infused with a sense of victory among supporters who attribute their economic recovery to Trump's policies. The focus on tariffs underscored their significance in this perceived resurgence. Andrew Saville, the president of Coosa Steel, gave a passionate endorsement of the tariffs, stating, "All the jobs that were going to China, you brought them back, and it really took us to the next level!" His words illuminated the transformation at Coosa Steel, going from the brink of failure to operating at full capacity. Saville emphasized the toll that foreign competition had taken on domestic businesses, noting, "The thing that took us right to the top was your tariffs. I think everybody in here that runs a small business, the tariffs had an effect on you one way or another." This endorsement served as powerful evidence of the impact Trump's trade policies have had on local industries. The rally served not only as a platform for Trump's economic discourse but also as a means of supporting a roster of Republican candidates leading up to upcoming elections. Coosa Steel Corporation became a symbol of the agenda aimed at restoring American jobs by protecting local manufacturing from international competition. Initially introduced during Trump's presidency, the tariffs included heavy taxes on foreign steel to counteract the low-price competition from countries like China. Trump framed these tariffs as essential to his strategy for rejuvenating American manufacturing, imposing fees of up to 50% on imported steel and its derivatives to champion domestic production. Steel workers at Coosa reaffirmed their support for these policies. Employee Jeffrey Shook remarked, "Our trucks are rolling out of here at near-max capacity every day," echoing Tyler King's observation that, "Business is climbing every day." These statements reflect a significant increase in productivity and activity since the implementation of tariffs, aligning with claims of economic revitalization. While some economists have questioned the effectiveness of protectionist tariffs, the rally functioned as a robust counter-argument. Trump, backed by White House officials, shared estimates claiming tax savings exceeding $3,000 per family in Georgia, along with promises of wage increases of approximately $6,700 for workers over the next few years. This gathering wasn't limited to the steel industry; it showcased a broader trend of business investments throughout Georgia. Major companies like Amazon and Salesforce were highlighted as key players in driving infrastructure development and job growth, emphasizing an ongoing theme of American economic renewal. However, not all was uncontested. Trump made strong claims regarding lower drug prices and job safeguarding that lacked extensive independent verification. Nonetheless, the rally retained a patriotic and revivalist theme, presenting policy-driven narratives designed to garner support within Georgia's political climate. The event underscored an underlying current of economic nationalism that Trump has championed. The development of Novartis' plan to construct drug manufacturing plants in the U.S., incentivized by tariffs, was pointed out as another indication of this economic turnaround. Saville referred to the improvement in business conditions as a "game changer," with orders and production possibilities reaching new levels. As the rally concluded, Trump reiterated his administration's achievements as a roadmap for America's future, placing them in stark contrast to the economic strategies of the current administration. By blending economic policy with electoral campaigning, the rally aimed to celebrate tangible successes while rallying support as the political landscape in Georgia shifts. Overall, the event at Coosa Steel represented a significant chapter in an era focused on prioritizing domestic interests over international ones. Supported by endorsements like Saville's, Trump's tariffs and their purported successes have emerged as a foundational element of his political and economic narrative.
NIPER Mohali partners Novartis to boost pharma research with prestigious Grant. NIPER Mohali partners Novartis to boost pharma research with the Development Pioneer Grant, driving innovation and industry-academia collaboration. National Institute of Pharmaceutical Education and Research (NIPER), Mohali, has signed a landmark agreement with Novartis Healthcare Private Limited (NHPL) to strengthen academia-industry collaboration in pharmaceutical research. The partnership includes the prestigious Development Pioneer Grant, awarded to a NIPER Mohali faculty member, positioning India's pharma education ecosystem closer to global innovation standards. The signing ceremony, held in New Delhi, was witnessed by Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, along with senior officials and representatives from Novartis. The Development Pioneer Grant. * Agreement signed between NIPER Mohali and Novartis Healthcare Private Limited (NHPL) in New Delhi. * Witnessed by Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. * One faculty member from NIPER Mohali awarded the Development Pioneer Grant for NIPERs, supported by Novartis. * Out of 42 proposals submitted across seven NIPERs, one was chosen after rigorous evaluation by an independent jury. * Grant aims to promote cutting-edge research, encourage innovation-driven partnerships, and align academic work with industry requirements. Government's vision. The Department of Pharmaceuticals has consistently highlighted the need for stronger industry-academia linkages. Senior officials including Shri Awadhesh Kumar Choudhary, Dr. Kinny Singh, Prof. Dulal Panda, Prof. Joydev Kumar Laha, Mr. Amitabh Dube, and Ms. Sadhna Joglekar were present during the ceremony, underscoring the government's commitment to nurturing innovation in India's pharmaceutical sector. Rare Earth Resources * Shri Manoj Joshi emphasized the importance of moving beyond pilot projects to ensure research is effectively integrated with industry needs. * The Department of Pharmaceuticals envisions stronger industry-academia linkages to enhance India's role in global healthcare innovation. * Senior officials including Shri Awadhesh Kumar Choudhary, Dr. Kinny Singh, Prof. Dulal Panda, Prof. Joydev Kumar Laha, Mr. Amitabh Dube, and Ms. Sadhna Joglekar attended the ceremony. About Novartis. Novartis, headquartered in Basel, Switzerland, is one of the world's leading pharmaceutical companies, consistently ranked among the top five globally by revenue. The company has undergone a strategic transformation into a pure-play medicines firm, focusing exclusively on innovative therapies while divesting non-core businesses such as generics and vaccines. In recent years, Novartis has reported strong growth driven by breakthroughs in oncology, immunology, cardio-renal-metabolic disorders, and neurology. It has also invested heavily in advanced platforms including radioligand therapy, gene and cell therapy, and xRNA technologies. Beyond commercial success, Novartis maintains a strong commitment to global health challenges, working on treatments for malaria, sickle cell disease, Chagas disease, and leprosy. This global positioning makes Novartis a powerful partner for Indian institutions like NIPER, enabling knowledge transfer, research collaboration, and integration into international innovation networks. Significance for India. * Strengthens NIPER Mohali's role in India's pharmaceutical innovation ecosystem. * Provides faculty with global exposure and competitive platforms to advance research. * Drives pioneering healthcare advancements that benefit both academia and industry. * Reinforces India's ambition to become a global hub for pharmaceutical innovation. The partnership between NIPER Mohali and Novartis marks a milestone in India's pharma education and research landscape. By combining academic expertise with industry resources, the initiative is set to accelerate innovation, nurture talent, and reinforce India's position in global pharmaceutical research.
A new market report projects growth in BRAF-mutated non-small cell lung cancer treatments through 2036 across the US, EU5 and Japan. The United States recorded nearly 201,200 NSCLC cases in 2022, with approximately 10,000 involving BRAF mutations, expected to increase substantially by 2034. Currently, only Novartis's Tafinlar and Mekinist combination therapy is approved for this mutation, having gained approval in 2017. The BRAF-mutated NSCLC market generated around $250 million in EU4 and UK markets in 2022. Emerging therapies in development include Plixorafenib and CFT1946, which target various BRAF mutations. The report identifies significant unmet medical needs and opportunities for new treatments, with market expansion anticipated through 2036 as new products enter clinical development.
After career in research, Lewis to join NCCN as chief scientific officer. A phase 1 clinical trial specialist, Nancy L. Lewis, MD, MBS, FACP, most recently spent more than a decade at Novartis and was previously a faculty member at Fox Chase Cancer Center and Thomas Jefferson University Hospital. Her career has taken her from treating patients to developing new medicines for biopharma, and now Nancy L. Lewis, MD, MBS, FACP, is ready for a new role: chief scientific officer for the National Comprehensive Cancer Network (NCCN), which announced her appointment today. Calling Lewis "the perfect person to oversee the work we do to foster innovation and knowledge discovery that improves the lives of people with cancer," NCCN CEO Crystal S. Denlinger, MD, said in a statement that the new CSO would be "an important asset to our leadership team as she helps us ensure our research and clinical programs continue to advance outcomes in oncology around the world." According to a statement from NCCN, Lewis holds degrees from Penn State University, Temple University School of Medicine, and Rutgers University. She completed her residency at the University of Rochester and fellowship at Fox Chase Cancer Center - one of NCCN's founding members. Lewis has been honored by the American Association for Cancer Research, the American Society of Clinical Oncology, and the American Cancer Society. She will join NCCN in May. NCCN is best known for its, which offer algorithmic approaches to diagnosis and treatment in 95% of cancers. The NCCN Guidelines, which are updated continuously, are considered the gold standard not only for physicians in treatment planning but also for payers in deciding what treatments will be reimbursed. Just days ago, Lewis concluded more than a decade with Novartis, where she was senior clinical program leader after serving many years as an associate professor Fox Chase and later with Thomas Jefferson University Hospital. A specialist in phase 1 clinical trials, Lewis spoke with The American Journal of Managed Care(R) about how the move to NCCN "allowed me to bring my career full circle." "Inthe first part of my career, I was taking care of patients in the clinic in the hospital, and I found it to be a pretty humbling experience," Lewis said. When she could offer a patient the opportunity to join a phase 1 trial, which might provide access to a promising drug, "that was really one of the most rewarding parts of my patient care experience." Lewis saw how much work it took to get a new drug from bench to bedside, which prompted her decision to move into industry. "That was a really rewarding part of my career as well. I worked on developing clinical trials - I worked with a huge number of investigators, whether they were bench scientists discovering new drugs, whether they were statisticians that were helping me design the trials - the preclinical safety groups. It was just an amazing experience in terms of understanding just what it took and how many people touch that protocol before it ever got to a patient," she said. She is "most passionate" about giving patients access to new therapies, which makes her new role at NCCN so appealing. Lewis looks forward to "working with NCCN to help establish the standard of care based on evidence, and I'm looking forward to working with the patient advocacy groups and the policy makers to ensure that all patients are granted access to these newer drugs." Lewis comes to her position at a crucial time. FDA is taking historic steps to shorten the time and reduce the number of trials needed to gain a drug approval, which could make NCCN's role more important than ever. As one who has seen the clinical trial process from many vantage points - and the difference that access to a trial can make in patients' lives - Lewis agrees with assessments that the approval process could take less time and cost much less money than it does. "It takes about 10 to 15 years and about $2 billion to identify a new drug and get it through the clinical trial process. And I would really like to see that streamlined," she said. "When I look at the amount of expertise and work and time and money that it actually takes for this process to come to fruition, we have to do better. And I think that we've got some tools that will enable us to do that in the not too distant future." Where does AI fit in among the solutions? "It's going to be an incredible tool for every process of the drug development pathway, from identifying new targets to predicting toxicities, to helping us design clinical trials that will give us appropriate endpoints to incorporating large, large data sets from the medical record, [such as] genetic registries," she said. "It's going to really streamline how we develop drugs and how we interpret the data. So, I'm looking forward to this new era, but cautiously." Stay ahead of policy, cost, and value - subscribe to AJMC for expert insights at the intersection of clinical care and health economics.